Global Community

Micron’s thesis has moved from “possible AI memory beneficiary” to a company where the AI memory supercycle is already visible in reported financials. The latest Micron investor deck shows FQ2 revenue of $23.9B, up 196% year over year, with non-GAAP gross margin of 74.9%, operating income of $16.5B and adjusted free cash flow of $6.9B.Read more

REN acquisition of Mirantis ($625M, all-stock) 1. Transaction overview Acquirer: IREN (AI infrastructure / former Bitcoin mining company) Target: Mirantis (cloud infrastructure & Kubernetes orchestration software) Deal value: ~$625M (stock consideration) [ growjo.com ] Announcement date: May 5, 2026 [ kearney.com ] Structure: Mirantis to operate as a standalone subsidiary [ kearney.com ] Mirantis brings: 1,500+ enterprise customers Kubernetes / AI infrastructure orchestration (k0rdent platform) [ kearney.com ] 2.Read more

A new push from Washington to speed up approvals for big data-centre builds could land right in IREN’s lap, since it’s already lining up large sites in Texas powered by renewable energy. The big question is whether it can execute fast enough to justify today’s high expectations as it shifts from bitcoin mining toward selling computing power for AI.Read more

One of China’s biggest made-to-order tea chains spreads fastest in smaller cities, using franchised shops and its own delivery network to keep quality consistent. That mix helps it grow quickly, but fierce price battles and uneven franchise execution could test the brand as the market crowds up.Read more

Glenveagh aims to solve Ireland’s housing shortage by building more homes with its own factory-style supply chain, rather than relying on stretched local contractors. The key question is whether government support and smoother planning can keep demand steady while rising wages and infrastructure gaps don’t squeeze profits.Read more

Investment Thesis DefenCath's regulatory moat (only FDA-approved antimicrobial CLS in the U.S., NCE+GAIN exclusivity through 2033, composition patent to 2042) is intact and the 72% real-world CRBSI reduction is standard-of-care quality data; the TDAPA pricing step-down is a commercial mechanics event, not a competitive displacement event The stock at $7.02 prices in approximately the bear case ($6.54), meaning investors are effectively receiving the REZZAYO prophylaxis Phase III binary and the DefenCath TPN pipeline for free — an unusual asymmetry for a cash-flow-positive commercial pharma company Operating cash flow of $175M in FY2025 and $148.5M in cash provides full self-funding of pipeline without dilution risk, and the $75M buyback at current prices represents management's explicit capital allocation conviction about intrinsic value The Melinta acquisition was well-priced ($30M goodwill on $391M identified intangibles) and adds an annualizing $130M+ revenue stream with shared call points that provide SG&A leverage as the combined platform scales Post-TDAPA recovery in 2027 (3x–5x higher add-on payment vs. H2 2026 per management, plus Medicare Advantage contracting upside not in guidance) provides a clearly identified catalyst path back to re-rating independent of pipeline success Risk Considerations ReSPECT Phase III failure (data Q2 2026) would eliminate ~$221M of base case rNPV, trigger impairment of the $143M IPR&D intangible, and likely reset the stock to the $5.60 52-week low or below — this is the primary binary risk and is near-term Customer concentration at 79% revenue from three accounts is structurally dangerous; any publicly announced reduction in DefenCath orders from a major dialysis organization would be a material negative event with little warning The Q4 GAAP EPS miss ($0.16 vs.Read more

A Japanese consulting and IT services firm is coming out of the gate with a much stronger start than expected, helped by growing demand from government and public-sector clients. Management is still talking down the rest of the year while investing more in people and new capabilities like AI, setting up a clear debate on whether the caution is realistic or overly conservative.Read more

PetroTal looks like a beaten-down oil producer that could bounce back if it keeps output steady and the export routes in Peru stay open. The catch is that local protests, transport bottlenecks, and a weaker oil market could quickly erase profits and leave the shares stuck near asset value.Read more

Rigetti is starting to look less like a science project and more like a real supplier, with early signs that customers are actually buying its quantum machines and using its cloud access. The catch: the company is still burning cash and has to hit tough technical goals, so even small stumbles could hit confidence fast.Read more